DEVELOPMENT, CHARACTERIZATION AND EVALUATION OF ENTRECTINIB NANOSPONGES LOADED TABLETS FOR ORAL DELIVERY

MAMATHA PALANATI; D. V. R. N. BHIKSHAPATHI

doi:10.22159/ijap.2023v15i6.49022

Authors

MAMATHA PALANATI Bir Tikandrajit University, Canchipur, Imphal West-795003, Manipur, India
D. V. R. N. BHIKSHAPATHI Bir Tikandrajit University, Canchipur, Imphal West-795003, Manipur, India

DOI:

https://doi.org/10.22159/ijap.2023v15i6.49022

Keywords:

Entrectinib, Cancer, Box–behnken design, Nanosponges, Tablets

Abstract

Objective: As Entrectinib is a lipophilic, basic, moderately permeable molecule with strongly pH-dependent solubility with antitumor activity in advanced and metastatic solid tumors, the current study was designed to improve the oral solubility of Entrectinib through incorporation into nanosponges tablets (NSs).

Methods: Box-Behnken Design was used to optimize the independent variables of β-Cyclodextrin (β-CD) NSs formation. β-CD NSs were prepared by an ultrasound-assisted method using diphenyl carbonate as cross-linking agent, which were later characterized and formulated into tablets by wet granulation method. The prepared tablets were evaluated for the physico-chemical properties and in vitro release of the drug.

Results: A series of fifteen experiments were performed based on the experimental runs generated from a three-factor, three-level Box–Behnken design (BBD). The range of mean particle size was 149-294 nm, the range for encapsulation efficiency % was 65.4%-87.3%, and the value for polydispersity index was 0.437. The zeta potential for the optimized formulation was found to be 38.1 Mv. The drug and excipients were compatibles as confirmed by Fourier Transformed Infrared (FTIR) Spectroscopy and Differential Scanning Calorimetry (DSC) studies. Scanning Electron Microscopic (SEM) analysis confirmed that the Entrectinib has successfully entrapped in the core of polymer. In vitro release of the Entrectinib-loaded NSs tablets (six compositions) were compared with a marked product and satisfactory results were obtained. It was observed that rapid dissolution occurred in 0.1 N HCl for first 2 h (15.64±1.52% vs. 12.67±1.89%) and 98.94±2.43% of drug release was observed in Entrectinib loaded NSs and 91.78±1.37% in marketed product in 24 h. The prepared formulations were stable during 6 mo stability study period.

Conclusion: The study results studies of Entrectinib NS tablets indicated rapid dissolution due to changed solubility properties of the drug, compared to pure drug meeting the set objective of enhanced absorption. The formulated Entrectinib-loaded NSs can be beneficial in the treatment of cancers.

Downloads

Download data is not yet available.

References

Weinstein IB, Joe AK. Mechanisms of disease: oncogene addiction-a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006 Aug;3(8):448-57. doi: 10.1038/ncponc0558, PMID 16894390.

Drilon A, Siena S, Ou SI, Patel M, Ahn MJ, Lee J. Safety and antitumor activity of the multitargeted pan-TRK, ROS1, and ALK inhibitor entrectinib: combined results from two phase I trials (ALKA-372-001 and STARTRK-1). Cancer Discov. 2017 Apr;7(4):400-9. doi: 10.1158/2159-8290.CD-16-1237, PMID 28183697.

Meneses Lorente G, Bentley D, Guerini E, Kowalski K, Chow Maneval E, Yu L. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. Invest New Drugs. 2021 Jun;39(3):803-11. doi: 10.1007/s10637-020-01047-5, PMID 33462752.

Parrott N, Stillhart C, Lindenberg M, Wagner B, Kowalski K, Guerini E. Physiologically based absorption modelling to explore the impact of food and gastric pH changes on the pharmacokinetics of entrectinib. AAPS J. 2020 May 26;22(4):78. doi: 10.1208/s12248-020-00463-y, PMID 32458089.

Meneses Lorente G, Bentley D, Guerini E, Kowalski K, Chow Maneval E, Yu L. Characterization of the pharmacokinetics of entrectinib and its active M5 metabolite in healthy volunteers and patients with solid tumors. Invest New Drugs. 2021 Jun;39(3):803-11. doi: 10.1007/s10637-020-01047-5, PMID 33462752.

Al-Salama ZT, Keam SJ. Entrectinib: first global approval. Drugs. 2019 Sep;79(13):1477-83. doi: 10.1007/s40265-019-01177-y, PMID 31372957.

Sharma M, Sharma R, Jain DK. Nanotechnology-based approaches for enhancing oral bioavailability of poorly water soluble antihypertensive drugs. Scientifica (Cairo). 2016 Apr;2016:8525679. doi: 10.1155/2016/8525679, PMID 27239378.

Kanugo A, Misra A. New and novel approaches for enhancing the oral absorption and bioavailability of protein and peptides therapeutics. Ther Deliv. 2020 Nov;11(11):713-32. doi: 10.4155/tde-2020-0068, PMID 33225869.

Gupta M. Inorganic nanoparticles: an alternative therapy to combat drug-resistant infections. Int J Pharm Pharm Sci. 2021 Aug;13(8):20-31. doi: 10.22159/ijpps.2021v13i8.42643.

Sarvan, Vashisth H. Types and application of pharmaceutical nanotechnology: a review. Int J Curr Pharm Sci 2023;15(3):14-8. doi: 10.22159/ijcpr.2023v15i3.3010.

Ankem B, Kucharlapati SLT, Magapu SD, BB. Nanosponges-a revolutionary targeted drug delivery nanocarrier: a review. Asian J Pharm Clin Res. 2023 Apr;16(4):3-9. doi: 10.22159/ajpcr.2023.v16i4.46453.

Subair TK, Mohanan J. Development of nano-based film forming gel for prolonged dermal delivery of luliconazole. Int J Pharm Pharm Sci. 2022 Feb;14(2):31-41. doi: 10.22159/ijpps.2022v14i2.43253.

Sharma P, Sharma A, Gupta A. Nanosponges: as a dynamic drug delivery approach for targeted delivery. Int J App Pharm. 2023 May;15(3):1-11. doi: 10.22159/ijap.2023v15i3.46976.

Mendes C, Meirelles GC, Barp CG, Assreuy J, Silva MAS, Ponchel G. Cyclodextrin based nanosponge of norfloxacin: intestinal permeation enhancement and improved antibacterial activity. Carbohydr Polym. 2018 Sep 1;195:586-92. doi: 10.1016/j.carbpol.2018.05.011, PMID 29805015.

Ponnagantimuralikrishna A, Palanatimamatha. Formulation and optimization of ceritinib loaded nanobubbles by box-behnken design. Int J Appl Pharm. 2022 Jul;14(4):219-26.

Politis SN, Colombo P, Colombo G, Rekkas DM. Design of experiments (DoE) in pharmaceutical development. Drug Dev Ind Pharm. 2017 Jun;43(6):889-901. doi: 10.1080/03639045.2017.1291672.

Konda M, Sampathi S. Qbd approach for the development of capsaicin-loaded stearic acid-grafted chitosan polymeric micelles. Int J App Pharm. 2023 Jul;15(4):131-42. doi: 10.22159/ijap.2023v15i4.48101.

Sharma K, Kadian V, Kumar A, Mahant S, Rao R. Evaluation of solubility, photostability and antioxidant activity of ellagic acid cyclodextrin nanosponges fabricated by melt method and microwave-assisted synthesis. J Food Sci Technol. 2022 Mar;59(3):898-908. doi: 10.1007/s13197-021-05085-6, PMID 35153320.

Aldawsari MF, Alhowail AH, Anwer MK, Ahmed MM. Development of diphenyl carbonate-crosslinked cyclodextrin based nanosponges for oral delivery of baricitinib: formulation, characterization and pharmacokinetic studies. Int J Nanomedicine. 2023 Apr;18:2239-51. doi: 10.2147/IJN.S405534, PMID 37139486.

Anwer MK, Ahmed MM, Aldawsari MF, Iqbal M, Kumar V. Preparation and evaluation of diosmin-loaded diphenyl carbonate-cross-linked cyclodextrin nanosponges for breast cancer therapy. Pharmaceuticals (Basel). 2022 Dec;16(1):19. doi: 10.3390/ph16010019, PMID 36678517.

Patel M, Sawant K. A quality by design concept on lipid-based nanoformulation containing antipsychotic drug: screening design and optimization using response surface methodology. J Nanomed Nanotechnol. 2017 May;08(3):1-11. doi: 10.4172/2157-7439.1000442.

Rezaei A, Varshosaz J, Fesharaki M, Farhang A, Jafari SM. Improving the solubility and in vitro cytotoxicity (anticancer activity) of ferulic acid by loading it into cyclodextrin nanosponges. Int J Nanomedicine. 2019 Jun;14:4589-99. doi: 10.2147/IJN.S206350, PMID 31296988.

Sherje AP, Dravyakar BR, Kadam D, Jadhav M. Cyclodextrin-based nanosponges: a critical review. Carbohydr Polym. 2017;173:37-49. doi: 10.1016/j.carbpol.2017.05.086, PMID 28732878.

Moin A, Roohi NKF, Rizvi SMD, Ashraf SA, Siddiqui AJ, Patel M, Ahmed SM, Gowda DV, Adnan M. Design and formulation of polymeric nanosponge tablets with enhanced solubility for combination therapy. RSC Adv. 2020 Sep;10(57):34869-84.

Khan A. Prediction of quality attributes (mechanical strength, disintegration behavior and drug release) of tablets on the basis of characteristics of granules prepared by high shear wet granulation. PLOS ONE. 2021 Dec;16(12):e0261051. doi: 10.1371/journal.pone.0261051, PMID 34882723.

Khan I, Lau K, Bnyan R, Houacine C, Roberts M, Isreb A. A facile and novel approach to manufacture paclitaxel-loaded proliposome tablet formulations of micro or nano vesicles for nebulization. Pharm Res. 2020 Jun;37(6):116. doi: 10.1007/s11095-020-02840-w, PMID 32488363.

Tafere C, Yilma Z, Abrha S, Yehualaw A. Formulation, in vitro characterization and optimization of taste-masked orally disintegrating co-trimoxazole tablet by direct compression. PLOS ONE. 2021 Mar;16(3):e0246648. doi: 10.1371/journal.pone.0246648, PMID 33725014.

Celik B. Risperidone mucoadhesive buccal tablets: formulation design, optimization and evaluation. Drug Des Devel Ther. 2017 Nov;11:3355-65. doi: 10.2147/DDDT.S150774, PMID 29225461.

Abbasnezhad N, Kebdani M, Shirinbayan M, Champmartin S, Tcharkhtchi A, Kouidri S. Development of a model based on physical mechanisms for the explanation of drug release: application to diclofenac release from polyurethane films. Polymers (Basel). 2021 Apr;13(8):1230. doi: 10.3390/polym13081230, PMID 33920267.

Kemkar K, SL, Sathiyanarayanan A, Mahadik K. 6-shogaol rich ginger oleoresin loaded mixed micelles enhances in vitro cytotoxicity on mcf-7 cells and in vivo anticancer activity against dal cells. Int J Pharm Pharm Sci. 2018 Jan;10(1):160-8. doi: 10.22159/ijpps.2018v10i1.23077.

An JY, Yang HS, Park NR, Koo TS, Shin B, Lee EH. Development of polymeric micelles of oleanolic acid and evaluation of their clinical efficacy. Nanoscale Res Lett. 2020;15(1):133. doi: 10.1186/s11671-020-03348-3, PMID 32572634.

Kovacs A, Berko S, Csanyi E, Csoka I. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the quality by design method. Eur J Pharm Sci. 2017r;99:246-57. doi: 10.1016/j.ejps.2016.12.020, PMID 28012940.

Tejashri G, Amrita B, Darshana J. Cyclodextrin based nanosponges for pharmaceutical use: a review. Acta Pharm. 2013 Sep;63(3):335-58. doi: 10.2478/acph-2013-0021, PMID 24152895.

Tiwari K, Bhattacharya S. The ascension of nanosponges as a drug delivery carrier: preparation, characterization, and applications. J Mater Sci Mater Med. 2022 Mar;33(3):28. doi: 10.1007/s10856-022-06652-9, PMID 35244808.

Utzeri G, Matias PMC, Murtinho D, Valente AJM. Cyclodextrin-based nanosponges: overview and opportunities. Front Chem. 2022 Mar;10:859406. doi: 10.3389/fchem.2022.859406, PMID 35402388.

Schwarz C, Mehnert W. Freeze-drying of drug-free and drug-loaded solid lipid nanoparticles (SLN). Int J Pharm. 1997 Nov;157(2):171-9. doi: 10.1016/s0378-5173(97)00222-6, PMID 10477814.

Shaikh MV, Kala M, Nivsarkar M. Formulation and optimization of doxorubicin loaded polymeric nanoparticles using box-behnken design: ex-vivo stability and in vitro activity. Eur J Pharm Sci. 2017;100:262-72. doi: 10.1016/j.ejps.2017.01.026, PMID 28126560.

Wei TK, Manickam S. Response surface methodology, an effective strategy in the optimization of the generation of curcumin‐loaded micelles. Asia-Pacific J Chem Eng. 2012 Jan;7(S1)Suppl 1:125-33. doi: 10.1002/apj.661.

Danaei M, Dehghankhold M, Ataei S, Hasanzadeh Davarani F, Javanmard R, Dokhani A. Impact of particle size and polydispersity index on the clinical applications of lipidic nanocarrier systems. Pharmaceutics. 2018 May;10(2):57. doi: 10.3390/pharmaceutics10020057, PMID 29783687.

Abbas G, Hanif M, Khan MA. pH responsive alginate polymeric rafts for controlled drug release by using box behnken response surface design. Des Monomers Polym. 2017 Sep;20(1):1-9. doi: 10.1080/15685551.2016.1231046, PMID 29491774.

Sharma RK, Yassin AE. Nanostructure-based platforms-current prospective in ophthalmic drug delivery. Indian J Ophthalmol. 2014 Jul;62(7):768-72. doi: 10.4103/0301-4738.138301, PMID 25116766.

Torne SJ, Ansari KA, Vavia PR, Trotta F, Cavalli R. Enhanced oral paclitaxel bioavailability after administration of paclitaxel-loaded nanosponges. Drug Deliv. 2010 Aug;17(6):419-25. doi: 10.3109/10717541003777233, PMID 20429848.

Kovacs A, Berko S, Csanyi E, Csoka I. Development of nanostructured lipid carriers containing salicyclic acid for dermal use based on the quality by design method. Eur J Pharm Sci. 2017;99:246-57. doi: 10.1016/j.ejps.2016.12.020, PMID 28012940.

Tardy BL, Mattos BD, Otoni CG, Beaumont M, Majoinen J, Kamarainen T. Deconstruction and reassembly of renewable polymers and biocolloids into next generation structured materials. Chem Rev. 2021 Nov;121(22):14088-188. doi: 10.1021/acs.chemrev.0c01333, PMID 34415732.

Sengupta P, Chatterjee B, Tekade RK. Current regulatory requirements and practical approaches for stability analysis of pharmaceutical products: a comprehensive review. Int J Pharm. 2018;543(1-2):328-44. doi: 10.1016/j.ijpharm.2018.04.007, PMID 29635054.